{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:57:32Z","timestamp":1793656652901,"version":"4.5.1"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.ahj.2025.03.017","type":"journal-article","created":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T15:10:30Z","timestamp":1743606630000},"page":"41-51","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Effects of angiotensin-neprilysin inhibition in women vs men: Insights from PARAGLIDE-HF"],"prefix":"10.1016","volume":"288","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2218-6742","authenticated-orcid":false,"given":"Paula","family":"Rambarat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler","family":"Erickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Cyr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Morrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randall","family":"Starling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Velazquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelley","family":"Zieroth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Williamson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Mentz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2025.03.017_bib0001","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/ejhf.67","article-title":"Sex-specific cardiovascular structure and function in heart failure with preserved ejection fraction","volume":"16","author":"Gori","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ahj.2025.03.017_bib0002","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1093\/eurheartj\/ehs070","article-title":"Discriminating clinical features of heart failure with preserved vs. reduced ejection fraction in the community","volume":"33","author":"Ho","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2025.03.017_bib0003","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ejheart.2006.10.012","article-title":"Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM","volume":"9","author":"Lewis","year":"2007","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ahj.2025.03.017_bib0004","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jchf.2019.01.003","article-title":"Sex differences in outcomes and responses to spironolactone in heart failure with preserved ejection fraction: a secondary analysis of TOPCAT trial","volume":"7","author":"Merrill","year":"2019","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.ahj.2025.03.017_bib0005","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.119.044491","article-title":"Effects of Sacubitril-Valsartan versus Valsartan in women compared with men with heart failure and preserved ejection fraction","volume":"141","author":"McMurray","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2025.03.017_bib0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2023.04.019","article-title":"Angiotensin-neprilysin inhibition in patients with mildly reduced or preserved ejection fraction and worsening heart failure","volume":"82","author":"Mentz","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2025.03.017_bib0007","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.cardfail.2023.02.001","article-title":"Rationale, design and baseline characteristics of the PARAGLIDE-HF trial: sacubitril\/Valsartan vs Valsartan in HFmrEF and HFpEF with a worsening heart failure event","volume":"29","author":"Mentz","year":"2023","journal-title":"J Card Fail"},{"key":"10.1016\/j.ahj.2025.03.017_bib0008","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/pst.1763","article-title":"A generalized analytic solution to the win ratio to analyze a composite endpoint considering the clinical importance order among components","volume":"15","author":"Dong","year":"2016","journal-title":"Pharm Stat"},{"key":"10.1016\/j.ahj.2025.03.017_bib0009","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1080\/10543406.2017.1397007","article-title":"The stratified win ratio","volume":"28","author":"Dong","year":"2018","journal-title":"J Biopharm Stat"},{"key":"10.1016\/j.ahj.2025.03.017_bib0010","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/1467-9868.00259","article-title":"Semiparametric regression for the mean and rate functions of recurrent events","volume":"62","author":"Lin","year":"2000","journal-title":"J Royal Statistic Soc Series B"},{"key":"10.1016\/j.ahj.2025.03.017_bib0011","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.jacc.2007.04.064","article-title":"Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry","volume":"50","author":"Fonarow","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2025.03.017_bib0012","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.jacc.2024.02.035","article-title":"Sacubitril\/Valsartan-related hypotension in patients with heart failure and preserved or mildly reduced ejection fraction","volume":"83","author":"Fo\u00e0","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2025.03.017_bib0013","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/j.cardfail.2024.04.030","article-title":"Association of Sacubitril\/Valsartan versus Valsartan with blood pressure changes, and symptomatic hypotension: the PARAGLIDE-HF trial","volume":"30","author":"Fudim","year":"2024","journal-title":"J Card Fail"},{"key":"10.1016\/j.ahj.2025.03.017_bib0014","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1161\/CIRCULATIONAHA.118.034271","article-title":"Sex differences in cardiovascular pathophysiology: why women are overrepresented in heart failure with preserved ejection fraction","volume":"138","author":"Beale","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2025.03.017_bib0015","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1002\/ehf2.14761","article-title":"Representativeness of the PIONEER-HF and PARAGLIDE-HF in patients hospitalized with acute heart failure","volume":"11","author":"Chen","year":"2024","journal-title":"ESC Heart Fail"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870325000997?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870325000997?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T07:52:11Z","timestamp":1749023531000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870325000997"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":15,"alternative-id":["S0002870325000997"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2025.03.017","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of angiotensin-neprilysin inhibition in women vs men: Insights from PARAGLIDE-HF","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2025.03.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}